Morpholino

MO2-ptgs2a

ID

ZDB-MRPHLNO-050722-6

Name

MO2-ptgs2a

Previous Names

MO2-ptgs2
zCOX-2-B (1)

Target

ptgs2a (1)

Sequence

5' - GCTGTTGAAGCAGAGATGCGTTACT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

designed against 5'-UTR

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO2-ptgs2a

No data available

Phenotype

Phenotype resulting from MO2-ptgs2a

Phenotype	Fish	Figures
brain ventricular system edematous, abnormal	WT + MO2-ptgs2a	Fig. 5 from Jin et al., 2014
cilium assembly decreased process quality, abnormal	WT + MO2-ptgs2a	Fig. 5 from Jin et al., 2014
lateral crista has fewer parts of type lateral crista kinocilium, abnormal	WT + MO2-ptgs2a	Fig. 5 from Jin et al., 2014

Phenotype of all Fish created by or utilizing MO2-ptgs2a

Phenotype	Fish	Conditions	Figures
exocrine pancreas prss1 expression amount, ameliorated	WT + MO1-ptgs2a + MO2-ptgs2a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
exocrine pancreas prss1 expression decreased distribution, abnormal	WT + MO1-ptgs2a + MO2-ptgs2a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas size, ameliorated	WT + MO1-ptgs2a + MO2-ptgs2a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	WT + MO1-ptgs2a + MO2-ptgs2a	control	Fig. 2 from Nissim et al., 2014
hematopoietic stem cell decreased amount, abnormal	WT + MO1-ptgs2a + MO2-ptgs2a	standard conditions	Fig. S1 from North et al., 2007
cilium assembly decreased process quality, abnormal	WT + MO2-ptgs2a	standard conditions	Fig. 5 from Jin et al., 2014
brain ventricular system edematous, abnormal	WT + MO2-ptgs2a	standard conditions	Fig. 5 from Jin et al., 2014
lateral crista has fewer parts of type lateral crista kinocilium, abnormal	WT + MO2-ptgs2a	standard conditions	Fig. 5 from Jin et al., 2014
liver EGFP expression decreased distribution, abnormal	as3Tg + MO1-ptgs2a + MO2-ptgs2a	control	Fig. 1 from Nissim et al., 2014
liver size, ameliorated	as3Tg + MO1-ptgs2a + MO2-ptgs2a	chemical treatment: prostaglandin E2	Fig. 1 from Nissim et al., 2014
liver EGFP expression amount, ameliorated	as3Tg + MO1-ptgs2a + MO2-ptgs2a	chemical treatment: prostaglandin E2	Fig. 1 from Nissim et al., 2014
liver decreased size, abnormal	as3Tg + MO1-ptgs2a + MO2-ptgs2a	control	Fig. 1 from Nissim et al., 2014
exocrine pancreas size, ameliorated	zf578Tg + MO1-ptgs2a + MO2-ptgs2a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	zf578Tg + MO1-ptgs2a + MO2-ptgs2a	control	Fig. 2 from Nissim et al., 2014
brain ventricular system edematous, abnormal	WT + MO1-ptgs1 + MO2-ptgs2a	standard conditions	Fig. 5 from Jin et al., 2014

Citations